| INTRODUCTION
Stroke is the clinically relevant outcome of several complex biological processes and pathways that involve metabolic, behavioral, environmental, and genetic factors.
1,2 Individuals of African ancestry are at higher risk and experience poorer outcomes than most other racial groups in the world. [3] [4] [5] [6] Inherited genetic variations offer a possible explanation for the observed peculiarities of stroke in populations of
African ancestry, as well as the proportion of risk that remains unexplained by traditional and emerging risk factors alone. 7 The Apolipoprotein L1 (APOL1) gene has been identified as a risk locus for chronic kidney disease (CKD) in African Americans 8 and confirmed in Yoruba Nigerian CKD patients. 9 In Africa, APOL1 confers resistance to infection from Trypanosoma brucei brucei, one of the trypanosomes that cause African sleeping sickness; it is believed that its evolutionary history lies in its positive selection due to its protection against this disease. 10,11 Worldwide, the highest frequencies of APOL1-associated kidney variants are found in indigenous West Africans 10 among whom small vessel disease (SVD) ischemic stroke is the most common stroke phenotype. 12 Because of the close association between cerebral and glomerular small vessel diseases, the association of APOL1 with cerebral SVD stroke is worth exploring in this population.
Furthermore, in a recent meta analysis of Genome-Wide Association Studies on stroke among African Americans, four genetic loci (PITX2, HDAC9, CDKN2A/CDKN2B, and ZFHX3) previously associated with ischemic stroke in Caucasian ancestry were found to be associated. 13 The Stroke Investigative Research and Education Network (SIREN) study is exploring genetic factors in stroke among West Africans using multilevel approaches. 7, 14 In the current analysis, we hypothesized that in view of the shared characteristics and vulnerability of the microvascular beds of the brain and the kidney, and common factors in small vessel disease pathobiology, single nucleotide polymorphisms of the APOL1 gene associated with CKD would be associated with cerebral ischemic SVD among West Africans. We herein report the findings of a candidate gene study using SIREN genotyped and phenotyped data of SVD ischemic stroke vs stroke-free controls.
| METHODS

| Patient enrollment and data acquisition
The rationale and design of the SIREN study have been described elsewhere. 14 In brief, the SIREN study is a multicenter case-control study with several sites in Nigeria and Ghana. It was initiated in August 2014. The ethnographic characteristics of the study population are as previously described. 15 Ethical approval was obtained for all study sites, and informed consent was obtained from all subjects. Cases were consecutively recruited consenting adults (aged 18 years or older) with first clinical stroke within 8 days of current symptom onset or "last seen without a deficit" with confirmatory cranial CT or MRI scan performed within 10 days of symptom onset. We excluded individuals with stroke mimics, primary subarachnoid hemorrhage, and previous strokes which were not ascertained by neuroimaging. Stroke-free controls were also recruited, and stroke-free status was ascertained with a locally validated version of the Questionnaire for Verifying Stroke-Free Status (QVSFS). 16, 17 Relevant data were collected including basic demographic and lifestyle data (ethnicity, native language of the subjects and their parents, socioeconomic status, dietary patterns, routine physical activity, stress, depression, cigarette smoking, and alcohol use). Cardiovascular and anthropometric measurements were obtained using standard techniques, and neurologic assessment was carried out to assess neurologic deficits and ascertain stroke severity using the National Institute Table S1 . Lacunar or SVD stroke was defined as small subcortical infarcts <15 mm in diameter on either CT or MRI by a neuro-radiologist and confirmed independently by an adjudication panel using the TOAST criteria. 
| Selection of stroke candidate genes and SNPs
Through an extensive literature review, 23 single nucleotide polymorphisms (SNPs) from 14 candidate genes with published and/or suspected association with ischemic stroke risk were selected for genotyping (Table S2 ). The majority of these were SNPs already associated with ischemic strokes and validated in at least more than one cohort.
However, selection of the APOL1 G1 [rs73885319 and rs60910145]
was largely exploratory based on recent data suggesting increasing role of the APOL1 gene in cardiovascular disease in people of African ancestry. 21 
| Genotyping and quality control method
Genomic DNA was extracted from whole blood with Gentra Systems PUREGENE DNA purification kit (Qiagen Group) according to manufacturers' protocol. Genotyping was carried out on genomic DNA from 506 stroke cases and 506 stroke-free controls randomly selected from among the entire cohort of recruited subjects as described above.
The genotyping was performed at Northwest Genomics Center in Washington Seattle, USA, using an ABI TaqMan SNP genotyping assays by Design (Applied Systems) under conditions recommended by the manufacturer. Probe and primer sequences for each assay are available on request. Standard quality control procedures were applied to the genotype data using all SNPs on the chip. We also genotyped sickle cell SNP rs334 to control for confounding due to sickle cell trait.
| Excluded subjects
We excluded 4 samples with sickle cell anemia and 5 samples with missing genotype for rs334 (Table S3 ). After excluding participants whose genotype data did not pass quality control, the study sample consisted of a total of 913 subjects (430 ischemic stroke cases and 483 stroke-free controls). There were 154 SVD stroke patients among all ischemic stroke cases.
| Association methods
All statistical analyses were performed using PLINK1.9. We compared proportions or means by two-sided t tests and for stratified samples with respect to sex and we used chi-squared tests or
Fisher's exact test if the expected cell size was less than 5. All SNPs were in Hardy-Weinberg equilibrium except rs60910145 in APOL1 gene (P = 2.4 × 10 −6 ). Thus, we excluded APOL1 rs60910145 from further analysis. To test for associations between SVD stroke status and each single SNP, we used logistic regression method with SNP as a predictor variable using additive mode of inheritance. We modeled age, sex, ethnicity rs334 (sickle cell status), hypertension, diabetes, dyslipidemia, and waist-hip ratio risk (Yes/No) as covariates. Furthermore, we also performed sex-stratified logistic regression because of reported gender disparities in stroke prevalence, incidence, severity, and outcomes. [22] [23] [24] [25] Furthermore, we confirmed our significant findings using exact logistic regression analysis to ensure that our results were not affected by small or zero cell counts for covariates.
| RESULTS
| Subject characteristics and distribution of risk factors
The demographic and risk factor characteristics by case-control status are detailed in Table 1 . Age distribution was similar in cases and controls. There were no statistically significant differences between cases and controls with respect to age (P = .341), sex (P = .716), and ethnicity (P: .244-.917). The risk factors: hypertension (P < .0001), diabetes (P < .0001), dyslipidemia (P < .0001), and waist-hip ratio (P = .002) were significantly more frequent among cases compared to controls (Table 1) .
| Genotyping
We genotyped 23 candidate SNPs in 14 genes that have been previously associated with ischemic stroke risk (Table S2) , including APOL1 G1 SNP variants. We also genotyped HBB SNP rs334
as a surrogate SNP for sickle cell anemia. Genotypic distribution of rs334 is given in Table S3 (510 individuals were Table S4 . Sex-stratified versions of Table   S4 are presented in Table S5 and Table S6 for males and females, respectively.
| Association
We Table 2 .
Sex-stratified analysis results are shown in significant at 5% significance level ( Table 3 ). The logistic regression results on all covariates are shown in Table S8 for three significant SNPs (P-value<.05) for male-only analysis. We also included association results for all SNPs in Table S10 for male-only analysis. In females, all three SNPs in HDAC9 were significant at 5% significance level (see Table 3 ). Note that these three SNPs are in LD (Table   S12 ). The effect sizes and p-values for HDAC9 SNPs are detailed in Table 3 . The association results for all covariates are shown in the Table S11 for SNPs rs2107595, rs28688791, and rs11984041, respectively. The results of female-only association analyses for all SNPs are detailed in the Table S11 . Furthermore, the significance of rs73885319 (P-value = .007) in APOL1 and rs7412 (P-value = .001)
in ApoE in male-only analysis was confirmed using exact logistic regression with 20K burn in and 100K interactions ( Table 4 ). The exact logistic regression analysis failed to converge for the model with rs2383207 in CDKN2B/CDKN2B. Similarly, we analyzed HDAC9 SNPs using exact logistic regression. The SNPs rs2107595
(P-value=.053), rs28688791 (P-value = .053), and rs11984041 (Pvalue = .073) in HDAC9 showed a trend toward statistical significance in females only (Table 4) . between SVD ischemic stroke and APOL1 rs 73885319. We also examined 22 other polymorphisms reported to be associated with stroke and found several significant associations including rs2383207 in CDKN2A/CDKN2B; and rs2107595 and rs28688791
| DISCUSSION
in HDAC9. ), there are conflicting data on the extra-renal manifestations of APOL1 CKD.
T A B L E 2 SNP association P-values and corresponding odds ratio with confidence interval (CI) (All Subjects)
Among African Americans participating in the Jackson Heart Study, presence of two APOL1 risk alleles was associated with a 2-fold increased risk of atherosclerotic cardiovascular disease event 30 while the Cardiovascular Health Study reported lower risk of carotid atherosclerosis and death, 31, 32 larger gray matter volume, and lower white matter lesion volume. 33 The West African subregion harbors some of the highest frequencies of APOL1 globally ranging from 34.2% among the Yoruba ethnic group in Nigeria to 43.6% among the Akan ethnic group of Ghana; both of these ethnic groups 10 were included in the current study. The APOL1 polymorphism SNP rs73885319 has been linked with CKD in two ethnic groups in Nigeria-the Yoruba and the Igbo.
9,29
The vasculatures of the brain and the kidney share structural and functional characteristics, and cerebral and glomerular small vessel diseases have been linked through epidemiologic and mechanistic studies. 34, 35 CKD is an independent risk factor for the development of cerebrovascular disease, especially SVD. 36 In terms of disease mechanisms, the relationship between APOL1
and SVD ischemic stroke may be a direct effect of the expression of APOL1 in the human endothelium 37 or may be associated with the structural and functional changes induced by hypertension and other vascular risk factors. 38, 39 Hypertension-attributed changes in the kidney (arteriolosclerosis and nephrosclerosis) have been associated with the APOL1 kidney variants with more recent evidence suggesting that APOL1 variants induce hypertrophy and accelerated cell death in nephrocytes. 40, 41 Further cellular and molecular studies are needed to examine the influence of APOL1 on the substructures of the neurovascular system.
The nominal association of CDKN2A/CDKN2B rs2383207 and HDAC9 rs28688791 and rs2107595 coding variants with lacunar stroke in this study is also novel. Previous association of polymorphisms in both genes and stroke has been with the large artery atherosclerotic subtype of ischemic stroke specifically. 48 and intracranial aneurysms. 49 The CDKN2A/CDKN2B
genes are about 100 kb away from ANRIL and encode protein products with increased expression in vascular tissue. 49 Although the exact mechanisms of these closely associated genes are not conclusive, they have capacity to recruit epigenetic modifiers which can modulate the expression of cellular reprogramming and endothelial differentiation. 50 Increased ANRIL expression is also observed to inhibit apoptosis, increase cell proliferation, and enhance cell adhesion. These processes can compromise the integrity of the vascular endothelium, a process fundamental to the development of atherosclerosis that underlies ischemic brain events and shared by both SVD and LAA subtypes.
51
HDAC9 is localized on chromosome 7p21.1 and encodes histone deacetylase 9 which plays key roles in the regulation of chromatin structure and gene transcription. 52, 53 HDAC9 is ubiquitously expressed, at high levels in the brain, skeletal muscle, and cardiac tissue. 53, 54 The histone deacetylases also act on other substrates and are involved in the epigenetic upregulation and downregulation of other genes. 55 While the mechanisms by which variants in the HDAC9 region increase small vessel stroke risk are not immediately clear, a link to endothelial dysfunction, now believed, to be at the heart of SVD pathogenesis 56 offers a reasonable explanation. Promotion of carotid atherosclerosis explains its mechanistic relationship with LAA. 57 Epigenetic modification through histone deacetylation may compromise the vascular endothelium through transcriptional regulation of endothelial arginases or cholesterol efflux, activation of macrophages, increased blood-brain barrier permeability and consequent endothelial dysfunction 58 Alternatively HDAC9 could increase risk by altering brain ischemic responses and affect neuronal survival.
| Strengths, limitations, and future directions
This is the first report of an association between APOL-1 and SVD ischemic stroke. However, we only evaluated a limited number of SNPs identified in prior stroke genetic studies and were unable to study rare variants due to limited sample size, and thus lack of adequate power to observe small effect loci with multiple test correction. Secondly, we only explored variants in the APOL1 G1 haplotype which were previously associated with CKD in indigenous Nigerian Africans. The APOL1 G2 kidney variant (InDel) occurs at a lower frequency in the population and is generally more difficult to detect than APOL1 G1 variants. Complementary blood biomarker studies of the SNPs with significant association might also have been very useful. 59 The noninclusion of additional potential SVD loci (12q24 and FOXF2) is also a limitation to this study. But this will be explored in detail in the GWAS planned as the next line of action.
Because this preliminary study was not primarily designed to assess renal function, relevant parameters for estimating glomerular filtration rate are not available for all subjects whose data were analyzed.
With our novel observation of association of APOL-1 with SVD ischemic stroke, we do plan to assess relevant urinary and blood parameters in the subsequent phase of the project to enable us accurately characterize the renal function profile of the subjects. This will enable us to determine if the association between APOL-1 and SVD stroke is independent of (or mediated by) renal disease when we adjust for renal function as covariate in a larger sample size.
Furthermore, our future work will examine our current findings and other polymorphisms associated with SVD ischemic stroke 60 with greater power and breadth within the context of genome-wide association studies on the entire SIREN cohort of 6000 subjects;
external validation of findings in other genetic stroke cohorts and consortia, pathway-based analyses and functional genomic studies to facilitate translational applications. We will also explore established and novel polymorphisms in other stroke subtypes to more clearly understand the contributions of other genetic polymorphisms to the neurobiology of stroke in people of African ancestry and beyond. 15 
| CONCLUSIONS/IMPLICATIONS
We observed that the polymorphisms rs73885319 in APOL1, rs2383207 in CDKN2A/CDKN2B; and rs2107595 and rs28688791
in HDAC9 were associated with SVD ischemic stroke among West Africans. Our findings may have been enhanced by the higher heritability of stroke among African ancestry populations 61 as well as the higher allelic frequencies of the SNPs due to ecological adaptation. 10 Further research is needed to confirm these initial findings and explore the molecular mechanisms underpinning their expression.
Identification of corresponding molecular targets for diagnosis and treatment may have implications for the entire human race as all humans originated from Africa.
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